anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a treating method postponing onset of tumors threatening life and/or improving quality of life by further reducing tumor load.  <P>SOLUTION: The method for treating a mammal having a solid tumor (or tumor) comprises (a) a step of administering a first compound in an active amount containing β-lapachone or its derivative as an active ingredient to the mammal and (b) a step of administering G2/M phase drug in an active amount. The administration of a G1 and/or S phase drug such as β-lapachone in combination with a G2/M drug such as a taxane derivative (e.g. paclitaxel) resulted in synergistic reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PROBLEM TO BE SOLVED: To provide an adhesive for a ceramic which has excellent adhesion, is not influenced by service conditions, and has excellent water resistance by adding a particular acidic compd. to an adhesive for a ceramic and markedly increasing the amt. of a silane coupling agent used. SOLUTION: This adhesive for a ceramic comprises: a coating liq. comprising a silane coupling agent (a) and at least one acidic compd. (b) selected from among an org. carboxylic acid, an org. carboxylic acid anhydride, an inorg. acid, and an organophosphoric acid; a coating material comprising a polymerizable monomer (c), having no silicon atom, capable of being polymerizing upon application on a face coated with the coating liq. in the presence of a polymerization catalyst; a polymerization catalyst (d) which, when the coating material is applied, is incorporated into the coating material, the amt. of the coating liq. and the coating material used being such that the coverage of the silane coupling agent is 5 to 15wt.% of the total coverage on a wt. basis of the components (a), (b), (c), and (d). This adhesive is useful as an adhesive for ceramics, particularly medical ceramics.
PROBLEM TO BE SOLVED: To prepare an aloe tablet having a high hardness and extremely readily ingestible, not being disintegrated even by transportation, by making the tablet include an aloe powder and lactulose as active ingredients therein. SOLUTION: This tablet is prepared by including (A) an aloe powder and (B) lactulose as active ingredients. The amounts of the ingredients based on 1 g tablet are preferably 50-800 mg ingredient A and >=0.1 pt.wt. (more preferably 0.2-10 pts.wt.) ingredient B based on 1 pt.wt. ingredient A. The ingredient B is preferably of >=95% purity. The tablet is has preferably 6-15 kg hardness in either of the horizontal and the vertical directions and is capable of withstanding handling, etc., at the time of tableting and packaging. Furthermore, the tablet is not only capable of improving the productivity and product quality but also is excellent in palatability such as no sticking to the interior of an oral cavity at the time of ingestion.
This study analyses the arrival-cohort effects on the newborn birthweight of Latina women residing in Spain. First, it has been tested whether women of Latin American origin in Spain have an advantage in terms of birth outcomes, a pattern previously documented in the United States and referred to as the 'Latin American paradox'. Second, it has been examined whether this health advantage of Latina mothers varies by arrival cohort.A novel database provided by the Spanish National Statistics Office that links the 2011 Census with Natural Movement of the Population records from January 2011 to December 2015 has been used. Poisson regression models were applied to test for differences in the incidence rates of low birthweight (LBW) and high birthweight (HBW) among children of Latina and native mothers, controlling for various demographic, socio-economic, and birth characteristics.Two distinct arrival-cohort effects on perinatal health were observed. On one hand, first-generation Latina women were found to be at a lower risk of giving birth to LBW infants; however, they experienced a higher incidence of HBW during the study period. Second, Latina women of 1.5 generation, likely stressed by increased exposure to the receiving country, exhibited adverse birthweight results.
Breast cancer is the leading cause of cancer in women in China. Neoadjuvant chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Docetaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Both TC and TAC are effective regimens in the adjuvant setting. The most optimal regimen in the neoadjuvant treatment is however unknown. This is especially true in triple-negative or HER2 positive breast cancer. This study will evaluate the pCR rate of TAC and TC as neoadjuvant treatment for triple-negative or HER2 positive breast cancer.
Patients receive berzosertib IV over 60 minutes on day -7 and then weekly on day 2 and cisplatin IV over 30-60 minutes weekly on day 1. Patients also undergo radiation therapy once daily, 5 days a week. Treatment continues for up to 7 weeks in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT, or MRI throughout the study.
Cross-linked atelopeptide collagen that is substantially free of residual cross-linking agent is prepared by reconstituting atelopeptide collagen from solution by neutralizing the solution at a reduced temperature and a hypotonic ionic strength, crosslinking the reconstituted fibers in an aqueous medium at a concentration of 0.1 to 10 mg/ml with a crosslinking agent at a concentration of about 0.001% to about 0.05% by weight that forms covalent bonds with the collagen under conditions sufficient to produce a fibrous cross-linked collagen that has greater than about 15 free lysine residues per 1000 amino acid residues and that when in suspension in physiological saline at a concentration of 35 mg/ml exhibits a shear viscosity whose log varies linearly with the log of the shear rate and is approximated by the formula: log ? ?-0.96 log ? + 2.3 where ? is the shear rate in sec-1, log ? is in the range of -6 to +2 and ? is the viscosity of the suspension in Pascal-sec, optionally quenching the cross-linking reaction with an amino acid, and separating the cross-linked atelopeptide collagen from the reaction mixture. This collagen is dispersed in an isotonic aqueous medium for use in soft tissue dermal augmentation and is injectable and forms implants that have excellent persistence.
Spontaneous regression of non-small cell lung cancer is relatively rare. Here, we present a very rare case of spontaneous regression of lung cancer which occurred in a patient with basaloid squamous cell lung cancer. To the best of our knowledge, this is the first report of such a case. A 76-year old man was referred to our hospital with nodules in the right upper lobe determined by chest computed tomography. The nodules spontaneously regressed during follow-up. Two years later, the tumor had regrown and the patient subsequently underwent surgery. The pathological findings showed basaloid squamous cell carcinoma. Stimulation of the immune system was considered to be the cause of the spontaneous regression and CD-8 positive and CD-4 positive lymphocytes might play an important role.
Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).
679,738. Animal tissue extracts. LIVING- STON, W. S. Jan. 6, 1950, No. 395/50. Class 81 (i). A medicine for the treatment of cancer and virus diseases is obtained by subjecting animal tissue in water or in a physiological saline solution to necrosis and disintegration under pressure above atmospheric and separating from the resulting material a liquid product free from solids and fat. The pressure is preferably 15 to 100 lbs per sq. inch and may be developed in the container, or applied at the time of sealing. The pH should be adjusted to 6 to 9, and preferably 7. The incubation temperature is preferably that of the body temperature of the animal from which the tissue was taken. The duration of treatment is at least one month. It is preferred to exclude air from the container prior to sealing..According to examples, products are obtained from tissue consisting of (a) ovaries and uterus of dogs and cats (b) kidneys, adrenal glands, heart muscle and lymph nodes of dogs (c) dog testicles and (d) tumour tissue from the breast of a dog. Reference is made to the Cancer Act 1939.
Neuromuscular blocking agents are essential during surgical procedures to paralyze the body to avoid unnecessary movement during surgery. There are various medications, such as Sugammadex that are later used to reverse the effects of the neuromuscular blockade. The U.S. performs approximately 320,000 colectomies per year for benign and malignant conditions such as Ulcerative Colitis (UC). Bowel resection surgery removes a portion of small or large intestine. Currently, there is little available prospective outcomes data regarding the use of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (hour) to first bowel movement and tolerance for solid food (aka GI-2 recovery) following bowel resection surgery. The study team will be conducting a randomized triple-blind study (patient's assigned group is hidden from the patient, provider, and research team). Randomization is created by using an electronic randomizer. Upon consent, the patient's assignment (per the randomizer) will be submitted to the Investigational Drug Service (IDS) Pharmacy by a department employee with no direct patient interaction.
This invention relates to a formulation of psilocybin which addresses problems of uniformly dispersing the psilocybin active in the excipients. The formulation comprises psilocybin, a silicified filler, preferably silicified microcrystalline cellulose, and optionally a disintegrant, glidant and lubricant. The preferred disintegrant, glidant and lubricant are sodium starch glycolate, colloidal silicon dioxide and sodium stearyl fumurate respectively. The psilocybin is preferably in a crystalline form and may be polymorph A, polymorph A’, polymorph B or hydrate A. The preferred particle size range for the silicified microcrystalline cellulose excipient is 90-150 microns. The formulation may be an oral dosage form, particularly a tablet.
The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.
The sound overexposure is a major cause of hearing disorders. The installation of hearing disorders can be temporary or permanent. Most of the time the investigators see a rise in hearing thresholds that can be accompanied by tinnitus. However, sometimes-hearing disorders aren't characterized by higher auditory threshold but by a complaint of understanding in noise. Two explanation are the either possible with a lesion at the peripheral level (sensory organ) or central lesion (auditory pathways). Peripheral damage is easily analysed by conventional tests such as the audiogram. Concerning the central lesions, through to the Electrocochleography, one sees a diminution of the wave I which corresponds to the nerve fiber injury. The wave I can more easily be analysed by the Electrocochleography method. This technique previously used an electrode deposited trans-tympanically in contact with the sensory organ. But, the evolution of a non-invasive technique is now available. However, several assemblies of the electrode are then possible without knowing the impact of these on the morphology of the wave I. Moreover, no normative values are also referenced in the literature on the population without hearing problems. It's in this context that clinical study is carried out in order to optimize the technique on the assembly of the electrode and the acoustic stimulation delivered. After this analyses and obtaining an optimal technique it's envisaged to study the morphology of the wave I in healthy volunteers aged 18-25 years. A pre-inclusion visit will verify the volunteers doesn't have a hearing disorders through a questionnaire, otoscopy, tympanometry and audiometry. Then two steps will be realized. The first is to evaluate the morphology of wave I according to assembly of electrode and acoustic stimulation delivered (machine calibration or calibration in the external auditory canal). The second step will provide normative values for people 18-25 years old who aren't hearing-impaired. Volunteers will have the choice to participate in one or both stages. The aim is to obtain wave I reference values for Electrocochleography technique. The secondary objectives are to analyse the impact of the assembly of the electrode and the adaptation of the acoustic stimulation presented.
The destruction of the microvascular structure and function can seriously affect the survival and prognosis of patients with acute myocardial infarction (AMI). Nuciferine has a potentially beneficial effect in the treatment of cardiovascular disease, albeit its role in microvascular structure and function during AMI remains unclear. This study aimed to investigate the protective effect and the related mechanisms of nuciferine in microvascular injury during AMI. Cardiac functions and pathological examination were conducted in vivo to investigate the effect of nuciferine on AMI. The effect of nuciferine on permeability and adherens junctions in endothelial cells was evaluated in vitro, and the phosphorylation level of the PI3K/AKT pathway (in the presence or absence of PI3K inhibitors) was also analyzed. In vivo results indicated that nuciferine inhibited ischemia-induced cardiomyocyte damage and vascular leakage and improved cardiac function. In addition, the in vitro results revealed that nuciferine could effectively inhibit oxygen-glucose deprivation (OGD) stimulated breakdown of the structure and function of human coronary microvascular endothelial cells (HCMECs). Moreover, nuciferine could significantly increase the phosphorylation level of the PI3K/AKT pathway. Finally, the inhibitor wortmannin could reverse the protective effect of nuciferine on HCMECs. Nuciferine inhibited AMI-induced microvascular injury by regulating the PI3K/AKT pathway and protecting the endothelial barrier function in mice.
Lymphedema is a chronic condition causes by a lymphatic dysfunction that leads to the accumulation of fluid and fat in the limb. Here, the inventors identified the bioactive peptide apelin as good candidate to restore the lymphatic flow in lymphedema. They found a significant decrease in apelin expression in women lymphedematous arm compared to their normal arm. Using an apelin-knockout mouse model, they confirmed the crucial role of apelin as lymphedema was maintained more than 4 weeks after surgery and was associated with a lack of dermis lymphangiogenesis and increased dermal backflow. The inventors show that intradermal injection of apelin-lentivector significantly reduced limb swelling. This was associated with a reduction of dermis fibrosis and increase in lymphatic density. Importantly, apelin stimulates eNOS-mediated lymphatic pumping via Akt and eNOS phosphorylation in lymphatic endothelial cells (LEC). This was associated with significant increase in E2F8- targeted gene expression through the direct binding of E2F8 on CCBE1 promoter in LEC. Taken together, the results show that apelin plays a key role in lymphedema and thus represents a novel partner for VEGF-C to prevent limb swelling and tissue fibrosis in lymphedema.
The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
BACKGROUND: The purpose of this study was to determine the prevalence of unexpected positive cultures noted at the time of revision surgery for periprosthetic fracture (PPF) after total hip or knee arthroplasty. Moreover, we evaluated whether this finding should be considered clinically significant and what type of treatment, if any, was required.
METHODS: This was a single-center retrospective review of 270 patients undergoing surgery for PPFs from December 2010 to December 2021. Exclusion criteria included: open fractures; history of infection at fractured joint; non-operatively treated patients; and intraoperative fractures. The primary end point was the prevalence of unexpected positive cultures noted at the time of revision surgery. This was defined as one or more positive cultures in a PPF that the surgeon had preoperatively classified as aseptic according to the 2018 International Consensus Meeting. Data collection included patient demographics, medical histories, preoperative investigations, postoperative microbiology, and treatment.
RESULTS: During the study period, 159 patients were admitted with PPFs of the hip and 61 with PPFs of the knee. The mean age was 70 years (range, 32 to 93 years). Unexpected positive cultures were diagnosed postoperatively in 15 patients (6.8%; 10 hips, 5 knees). The most prevalent organism was Staphylococcus epidermidis (35.0%). Of those 15 patients, 6 required a surgical revision for infection. None of the patient-related risk factors were found to be associated with an increased risk of unexpected positive cultures. The comparison between infected and noninfected patients showed a significant association between preoperative C-reactive protein >10 mg/mL (P = .04), loose implant (P = .07), and infection.
CONCLUSIONS: The prevalence of unexpected positive cultures was 6.8% in our study cohort. Although surgical treatment may be required, the majority of patients seem to require no treatment. Larger series are required to investigate the clinical importance of this rare finding.
LEVEL OF EVIDENCE: III.
50 active drivers will be included in the study. The drivers included in the study will be randomly divided into two groups as exercise group and taping group. The home exercise program will be visually explained to both groups and the exercises will be sent to the participants as video. Kinesio® Tex will also be applied to the banding group. Evaluations will be made before treatment and after 6 weeks of treatment. Within the scope of the evaluation, demographic information of the patients, work experience, daily working time, dominant hand, education information (university / high school), type of vehicle used, habit of leaning elbow on the left window, diseases and drugs used, smoking and alcohol use, given after mutual interview will be obtained by recording the answers. Joint range of motion, manual muscle test, pain severity of the individuals participating in the study with the Visual Analog Scale, neck functionality assessment with the Neck Disability Indicator, back functionality assessment with the Quebec Back-Low Back Pain Disability Scale, sleep quality assessment with the Pittsburgh Sleep Quality Index, work performance assessment To be assessed by the Work Role Functioning Questionnaire
<P>PROBLEM TO BE SOLVED: To provide an improved medical solution which can easily be produced, stably and aseptically be maintained under a preservation condition, and easily and effectively be used during medical therapy such as dialysis therapy.  <P>SOLUTION: A glucose polymer-based solution and a method for making the glucose polymer-based solution that can be used during medical therapy such as dialysis therapy are provided. This glucose polymer-based solution preferably includes a first solution containing icodextrin at a pH ranging from about 1.5 to about 5.0 and a buffer solution at a pH ranging from about 7.0 to about 12.0. These first solution and buffer solution are constructed and arranged so as to allow the glucose polymer-based solution to be mixed prior to infusion into a patient. The glucose polymer-based solution can be made at a physiologic pH and with a minimal glucose degradation product.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Chronic daily headache encompasses a frequent headache state in which the increased burden of pain further compromises quality of life and adversely impacts patients, their families, and health care providers. Approximately 5% of patients with migraine, or an estimated 1.4 million Americans, manifest a chronic daily headache form of disease. The consequences include resistance to treatment, worsening quality of life, increased use and over use of medication, and development of ischemic and other neuropathological brain lesions. This is a randomized, double-blind, placebo-controlled multicenter study that will enroll patients 18-65 years old with an established history of migraine headaches who, in the 28 days prior to the study should have a migraine frequency of at least 10 but less than 15 migraine headache days per month, and less than 15 total headache days (migraine plus non migraine headaches) per month. The study duration will be approximately 26 weeks. The study is divided into 4 phases as follows: A Screening/Washout Phase that may last between 2-6 weeks, depending on whether you need to stop taking a medication that is not allowed in the study; A Baseline Phase lasting 4 weeks, at which time information will be collected on the migraine and non-migraine headaches you experience during this period; A double-blind Titration Phase lasting 4-6 weeks where all patients will be randomized to treatment with either Topiramate or placebo. If you are randomized to Topiramate, your dose will be gradually increased up to a dose of either 75 or 100 mg a day; A Maintenance Period lasting 20 weeks at which time you will continue on the dose you were taking at the completion of the Titration period; and a Taper/Exit phase, lasting 2 weeks, where you will gradually reduce the dose of study medication you were taking during the study. The study hypothesis is that the study drug will be more effective than placebo in preventing patients from transforming from episodic migraines to chronic daily headaches. Each patient will be asked to record their headache pain information and medication use on paper headache diaries. Patients will receive either Topiramate or placebo. The number of tablets of topiramate or placebo, will be gradually increased to either a minimum of 3 tablets/day or a maximum of 4 tablets/day. For those on Topiramate, 3 tablets would represent 75 mg and 4 tablets would represent 100 mg/day.
Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.